Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis

Journal of Thoracic Oncology

Volumn 11, Issue 8, 2016, Pages 1293-1304

  Noonan, Sinéad A ^a   Berry, Lynne ^b   Lu, Xian ^a   Gao, Dexiang ^a   Barón, Anna E ^a   Chesnut, Patrick ^a   Sheren, Jamie ^a   Aisner, Dara L ^a   Merrick, Dan ^a   Doebele, Robert C ^a   Varella Garcia, Marileila ^a   Camidge, D Ross ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Adrenal metastases; Lung adenocarcinoma; MET copy number gain; Oncogene overlap

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PROTEIN RET; MET PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR;

ADRENAL METASTASIS; ADULT; ARTICLE; CENTROMERE; CHROMOSOME 7; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DOSAGE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL EPITHELIAL TRANSITION FACTOR GENE; MIDDLE AGED; ONCOGENE; ONCOGENE N RAS; ONCOGENE NEU; PRIORITY JOURNAL; PROTO ONCOGENE; SMOKING; ADENOCARCINOMA; CENTROSOME; GENETICS; LUNG TUMOR; PROCEDURES; RETROSPECTIVE STUDY;

ADENOCARCINOMA; CENTROSOME; FEMALE; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONCOGENES; PROTO-ONCOGENE PROTEINS C-MET; RETROSPECTIVE STUDIES;

EID: 84982094993     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.04.033     Document Type: Article

References (42)

1. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:1998-2006.
2. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-246.
3. Planchard D, Kim TM, Mazières J, et al. Dabrafenib in patients with BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): a multicenter, open-label, phase II trial (BRF113928) [abstract]. Ann Oncol. 2014;25(suppl 4). LBA38-PR.
4. Camidge DR, Bang Y-J, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011-1019.
5. Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;372:683-684.
6. Guibert N, Ilie M, Long E, et al. KRAS mutations in lung adenocarcinoma: molecular and epidemiological characteristics, methods for detection, and therapeutic strategy perspectives. Curr Mol Med. 2015;15: 418-432.
7. Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18:4910-4918.
8. Ohashi K, Sequist LV, Arcila ME, et al. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res. 2013;19:2584-2591.
9. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18:375-377.
10. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003;22:309-325.
11. Gherardi E, Youles ME, Miguel RN, et al. Functional map and domain structure of MET, the product of the c-Met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A. 2003;100:12039-12044.
12. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984;311:29-33.
13. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251:802-804.
14. Gaule PB, Crown J, O'Donovan N, Duffy MJ. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients? Expert Opin Ther Targets. 2014;18:999-1009.
15. Noguchi E, Saito N, Kobayashi M, Kameoka S. Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression. Mol Med Rep. 2015;11:3423-3431.
16. Mesteri I, Schoppmann SF, Preusser M, Birner P. Overexpression of CMET is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in oesophageal adenocarcinoma but not in squamous cell carcinoma. Eur J Cancer. 2014;50: 1354-1360.
17. Lee J, Jain A, Kim P, et al. Activated cMET and IGF1Rdriven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status. PLoS One. 2014;9:e103551.
18. Balan M, Mier y Teran E, Waaga-Gasser AM, et al. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. J Biol Chem. 2015;290:8110-8120.
19. Li H, Zhang H, Zhao S, et al. Overexpression of MACC1 and the association with hepatocyte growth factor/c-Met in epithelial ovarian cancer. Oncol Lett. 2015;9: 1989-1996.
20. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005:1479-1488.
21. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12:89-103.
22. Schildhaus H-U, Schultheis AM, Rüschoff J, et al. MET amplification status in therapy-naïve adeno-and squamous cell carcinomas of the lung. Clin Cancer Res. 2015;21:907-915.
23. Paik PK, Drilon A, Fan P-D, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5:842-849.
24. Camidge DR, Ou SH, Shapiro G, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2014;32(suppl):8001.
25. Bean J, Brennan C, Shih J-Y, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007;104:20932-20937.
26. Beau-Faller M, Ruppert A-M, Voegeli A-C, et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol. 2008;3:331-339.
27. Casadevall D, Gimeno J, Clavé S, et al. MET expression and copy number heterogeneity in nonsquamous nonsmall cell lung cancer (nsNSCLC). Oncotarget. 2015;6:16215-16226.
28. Watermann I, Schmitt B, Stellmacher F, et al. Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation? Diagn Pathol. 2015;10:130.
29. Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009;27:1667-1674.
30. Bang Y-J, Su W-C, Nam D-H, et al. Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors [abstract]. J Clin Oncol. 2014:32 (suppl):2520.
31. Sholl LM, Aisner DL, Varella-Garcia M, et al. Multiinstitutional oncogenic driver mutation analysis in lung adenocarcinoma. J Thorac Oncol. 2015;10:768-777.
32. Wang L, Hu H, Pan Y, et al. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS One. 2014;9:e88291.
33. Chaft JE, Arcila ME, Paik PK, et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinomarationale for comprehensive mutation profiling. Mol Cancer Ther. 2012;11:485-491.
34. Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31: 3997-4013.
35. American Cancer Society. Cancer facts and figures 2015. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/index. Accessed February 1, 2016.
36. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306-13311.
37. D'Angelo SP, Pietanza MC, Johnson ML, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol. 2011;29:2066-2070.
38. Girard N, Sima CS, Jackman DM, et al. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J. 2012;39: 366-372.
39. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010;16:5581-5590.
40. Varella-Garcia M, Berry L, Su P-F, et al. ALK and MET genes in advanced lung adenocarcinomas: the Lung Cancer Mutation Consortium experience [abstract]. J Clin Oncol. 2012;30(suppl):7589.
41. Doebele RC, Lu X, Sumey C, et al. Oncogene status predicts patterns of metastatic spread in treatmentnaive nonsmall cell lung cancer. Cancer. 2012;118: 4502-4511.
42. Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016;34:721-730.